Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus (Q43945283)

28 November 2017

Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus (English)

1 reference

28 November 2017

1 reference

Wan Mohamad WB

1

1 reference

28 November 2017

Tun Fizi A

series ordinal

2

1 reference

28 November 2017

Ismail RB

series ordinal

3

1 reference

28 November 2017

Mafauzy M

series ordinal

4

1 reference

28 November 2017

1 August 2000

1 reference

Diabetes Research and Clinical Practice

28 November 2017

1 reference

28 November 2017

49

1 reference

28 November 2017

2-3

1 reference

28 November 2017

93-99

1 reference

Blood Glucose Variations and Clinical Experience with Glibenclamide in Diabetes Mellitus

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900138-8

7 January 2021

Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900138-8

7 January 2021

Comparison of pharmacokinetics and pharmacodynamics of short- and long-term glyburide therapy in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900138-8

7 January 2021

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900138-8

7 January 2021

The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900138-8

7 January 2021

Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900138-8

7 January 2021

The effects of glibenclamide on glucose homeostasis and lipoprotein metabolism in poorly controlled type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900138-8

7 January 2021

Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900138-8

7 January 2021

Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900138-8

7 January 2021

Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2800%2900138-8

7 January 2021

10.1016/S0168-8227(00)00138-8

Identifiers

DOI

1 reference

28 November 2017

1 reference